CHANCE - Candesartan in Hypertrophic Cardiomyopathy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
The primary hypothesis of the study is that treatment with AT1-R antagonist in patients with nonobstructive form of HCM will be first save, second will cause regression of myocardial hypertrophy.
Epistemonikos ID: b75d44913bd00888627289c1b109cf07d88d01d4
First added on: May 04, 2024